Ratings by Atlantic Equities (James Mainwaring)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/16/2022 | DexCom | DXCM | Maintain | Overweight (N/A) |
|
Details | ||
| 6/1/2022 | Medtronic, Inc. | MDT | Downgrade | Neutral (Overweight) |
99.08 (80.89) |
-18.36% | Details | |
| 4/14/2022 | Agilent | A | Maintain | Neutral (N/A) |
|
Details | ||
| 4/12/2022 | Agilent | A | Maintain | Neutral (N/A) |
|
Details | ||
| 11/1/2021 | Abbott Labs | ABT | Upgrade | Overweight (Neutral) |
128.89 (107.60) |
-16.52% | Details | |
| 10/27/2021 | Abbott Labs | ABT | Upgrade | Overweight (Neutral) |
128.13 (107.60) |
-16.02% | Details | |
| 4/15/2021 | Edwards Lifesciences | EW | New Coverage | Neutral (N/A) |
86.44 (87.23) |
0.91% | Details | |
| 4/15/2021 | Abbott Labs | ABT | New Coverage | Neutral (N/A) |
122.56 (128.13) |
4.54% | Details | |
| 4/15/2021 | Medtronic, Inc. | MDT | New Coverage | Overweight (N/A) |
123.63 (80.89) |
-34.57% | Details | |
| 4/15/2021 | Boston Scientific | BSX | New Coverage | Overweight (N/A) |
39.41 (68.57) |
73.99% | Details | |
| 4/15/2021 | DexCom | DXCM | New Coverage | Overweight (N/A) |
388.10 (133.89) |
-65.5% | Details | |
| 3/31/2021 | Illumina | ILMN | Downgrade | Neutral (Overweight) |
395.00 (125.01) |
-68.35% | Details |
